British Psilocybin Featured Image

British MP Urges PM Johnson to Cut Through Barriers to Psilocybin Research

Share on facebook
Share on twitter
Share on linkedin
Share on email

A British Conservative Member of Parliament urged UK Prime Minister Boris Johnson on Wednesday to bring down the barriers to research into psilocybin mushrooms and other controlled compounds. 

Tory MP Crispin Blunt said in the House of Commons that psychedelic substances such as psilocybin hold “exciting potential for improving mental health treatments for conditions such as depression, trauma and addiction.” 

Blunt added that removing the barriers for research into psilocybin and similar compounds for British scientific and academic institutions, as well as British pharmaceutical companies, would “enable the potential treatments into these most debilitating conditions to be delivered at the earliest possible opportunity.”

Johnson responded to the request saying he would get back to Blunt “as soon as possible.”

“We will consider the Advisory Council on the Misuse of Drugs recent advice on reducing barriers to research with controlled drugs,” Johnson said.

Psilocybin is a Class A substance under the UK Misuse of Drugs Act, alongside other psychedelics like MDMA and LSD. Blunt and other activists are pushing the government to reclassify the substance to facilitate medical and scientific research.

See Also
DEA Drug Quotas

Blunt told the BBC that the prime minister had given him an assurance earlier this year, committing to rescheduling psilocybin mushrooms for clinical research. 

A number of leading medical institutes — including Imperial College London and John Hopkins in Maryland — are looking into the potential therapeutic benefits of psychedelic substances including psilocybin, MDMA, ayahuasca, and LSD.

Psychedelic substances are reemerging in the healthcare sector as a potential treatment for various ailments. MDMA-assisted psychotherapy is on the cusp of being medicalized by the U.S. Food and Drug Administration as MAPS published its first Phase III clinical trial earlier this year. The FDA requires a second successful Phase III clinical trial, which is currently underway and could come as early as 2023.

DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT: The final revised quotas "reflect DEA’s estimates of the medical, scientific, research, and industrial needs of the United States for 2022." https://www.marijuanamoment.net/dea-again-boosts-2022-production-goals-for-psychedelics-like-psilocybin-mdma-and-dmt/

BREAKING: MAPS and Vine Ventures announce creation of $70m SPV to fund patient access infrastructure and research for MDMA-assisted therapy for PTSD.

@MAPS, @VineVentures

What do we want the future of #psychedelic business to look like? We attended the Ethics in Psychedelics panel at this month's #PsyCap, hosted by @MicrodoseHQ, for some perspectives from @JasonNajum, @PaulaKahn2020 and K'uychi Florez.

Full article: http://ow.ly/SvI650H2ihq

"Psilocybin can treat depression, alcoholism, PTSD, and even cluster headaches. Why is it still illegal?"

Couldn't have said it better. Quality work from @thewalrus.

Full article: http://ow.ly/yQGc50H2a6O

#clusterheadaches #psilocybin #psilocybinheals

BREAKING: This morning,@jyduclos granted 2 more Canadians sec.56 exemptions so they may legally access #psilocybintherapy for end-of-life distress.

44 patients supported by TheraPsil now have exemptions.

Minister, THANK YOU.

Please continue to approve ALL in medical need.

Load More...

Related Articles

Scroll To Top